Category: AstraZeneca Lung Cancer Failure Sparks 16 Percent Share Fall

AstraZeneca lung cancer failure sparks 16 percent share fall

  1. AstraZeneca lung cancer failure sparks 16 percent share fall  Reuters
  2. Mighty AstraZeneca Takes a Lickin’ on Failed Mystic Trial  Motley Fool
  3. AstraZeneca Plc’s (AZN) CEO Pascal Soriot on Q2 2017 Results – Earnings Call Transcript  Seeking Alpha
  4. AstraZeneca’s Missing Takeover Defense  Bloomberg
  5. AstraZeneca boss Pascal Soriot’s ‘pivotal’ year is turning out horribly  The Guardian
  6. Full coverage

from Business – Google News http://in.reuters.com/article/astrazeneca-cancer-idINKBN1AC2KS

Advertisements

AstraZeneca lung cancer failure sparks 16 percent share fall

  1. AstraZeneca lung cancer failure sparks 16 percent share fall  Nasdaq
  2. Immunotherapy Shakeup: AstraZeneca Inks Merck Deal as Drug Combo Fails  Xconomy
  3. AstraZeneca: Pipeline Woes  Seeking Alpha
  4. AstraZeneca’s Missing Takeover Defense  Bloomberg
  5. Drugs giant AstraZeneca plummets in value by £7bn after key lung cancer treatment flops tests  Telegraph.co.uk
  6. Full coverage

from Business – Google News http://www.nasdaq.com/article/astrazeneca-lung-cancer-failure-sparks-16-percent-share-fall-20170727-01536

AstraZeneca Lung Cancer Failure Sparks 16 Percent Share Fall

  1. AstraZeneca Lung Cancer Failure Sparks 16 Percent Share Fall  New York Times
  2. AstraZeneca shares plunge 16 percent as lung cancer study fails  CNBC
  3. AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment  TheStreet.com
  4. AstraZeneca’s Missing Takeover Defense  Bloomberg
  5. Full coverage

from Business – Google News https://www.nytimes.com/reuters/2017/07/27/business/27reuters-astrazeneca-results.html